Aligos Therapeutics, Inc. Annual Income Tax Expense (Benefit) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Aligos Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2019 to 2023.
  • Aligos Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $91K, a 214% increase year-over-year.
  • Aligos Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $274K, a 68.7% decline year-over-year.
  • Aligos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $795K, a 650% increase from 2022.
  • Aligos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $106K, a 25.9% decline from 2021.
  • Aligos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $143K, a 11.2% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $795K +$689K +650% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-12
2022 $106K -$37K -25.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-12
2021 $143K -$18K -11.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 $161K +$76K +89.4% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 $85K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.